X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (656) 656
oncology (598) 598
index medicus (515) 515
chemotherapy (456) 456
stomach neoplasms - drug therapy (407) 407
advanced esophagogastric cancer (383) 383
male (354) 354
female (351) 351
aged (335) 335
middle aged (329) 329
antineoplastic combined chemotherapy protocols - therapeutic use (308) 308
cancer (296) 296
stomach neoplasms - pathology (289) 289
adult (273) 273
treatment outcome (261) 261
advanced gastric-cancer (249) 249
cisplatin (249) 249
gastric cancer (243) 243
fluorouracil (225) 225
stomach cancer (200) 200
esophageal neoplasms - drug therapy (196) 196
adenocarcinoma - drug therapy (186) 186
fluorouracil - administration & dosage (176) 176
capecitabine (174) 174
adenocarcinoma (162) 162
antineoplastic combined chemotherapy protocols - adverse effects (158) 158
esophageal cancer (157) 157
surgery (152) 152
stomach neoplasms - mortality (145) 145
esophageal neoplasms - pathology (140) 140
care and treatment (129) 129
antineoplastic agents - therapeutic use (127) 127
phase-ii trial (127) 127
phase-iii trial (125) 125
advanced gastric cancer (123) 123
gastroenterology & hepatology (123) 123
oxaliplatin (123) 123
cisplatin - administration & dosage (120) 120
adenocarcinoma - pathology (119) 119
neoplasm staging (119) 119
1st-line therapy (118) 118
prognosis (118) 118
5-fluorouracil (116) 116
esophagogastric junction (116) 116
medicine & public health (114) 114
supportive care (113) 113
docetaxel (112) 112
metastasis (112) 112
disease-free survival (109) 109
aged, 80 and over (105) 105
survival rate (105) 105
trial (104) 104
research (99) 99
randomized-trial (97) 97
survival (93) 93
esophagogastric junction - pathology (90) 90
survival analysis (90) 90
folinic acid (89) 89
deoxycytidine - analogs & derivatives (88) 88
organoplatinum compounds - administration & dosage (88) 88
carcinoma (87) 87
open-label (87) 87
double-blind (86) 86
epirubicin (86) 86
clinical trials (85) 85
pharmacology & pharmacy (85) 85
gastroesophageal junction (83) 83
1st-line treatment (82) 82
antineoplastic combined chemotherapy protocols - administration & dosage (82) 82
fluorouracil - analogs & derivatives (82) 82
cancer research (80) 80
cancer therapies (80) 80
taxoids - administration & dosage (80) 80
plus cisplatin (78) 78
analysis (76) 76
adenocarcinoma - mortality (74) 74
deoxycytidine - administration & dosage (74) 74
squamous-cell carcinoma (73) 73
drug therapy (72) 72
esophageal neoplasms - mortality (71) 71
combined modality therapy (70) 70
drug administration schedule (70) 70
stomach neoplasms - surgery (70) 70
therapy (69) 69
doxorubicin (68) 68
combination chemotherapy (67) 67
esophageal neoplasms - therapy (67) 67
health aspects (67) 67
irinotecan (67) 67
metastatic colorectal-cancer (67) 67
combination (64) 64
neoplasm metastasis (64) 64
adjuvant chemotherapy (63) 63
stomach neoplasms - therapy (63) 63
retrospective studies (62) 62
fluorouracil - adverse effects (61) 61
tumors (61) 61
neoadjuvant chemotherapy (60) 60
phase-ii (60) 60
colorectal-cancer (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (839) 839
German (8) 8
French (3) 3
Spanish (2) 2
Chinese (1) 1
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2008, Volume 358, Issue 1, pp. 36 - 46
Journal Article
Journal Article
Surgical Oncology Clinics of North America, ISSN 1055-3207, 04/2017, Volume 26, Issue 2, pp. 293 - 312
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is... 
Esophagogastric junction cancer | VEGFR2 | Gastroesophageal adenocarcinoma | HER2 | Gastric cancer | MET | EGFR | FGFR2 | SURGERY | GASTROESOPHAGEAL JUNCTION | CETUXIMAB PLUS OXALIPLATIN/LEUCOVORIN/5-FLUOROURACIL | OPEN-LABEL | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | ONCOLOGY | ADVANCED GASTRIC-CANCER | C-MET | DOUBLE-BLIND | HER2 GENE AMPLIFICATION | PROGNOSTIC-SIGNIFICANCE
Journal Article
Jnci-Journal of the national cancer institute, ISSN 0027-8874, 10/2016, Volume 108, Issue 10, p. djw166
Journal Article
Journal Article
Acta Oncologica, ISSN 0284-186X, 12/2018, Volume 57, Issue 12, pp. 1599 - 1604
Introduction: After progression on first-line trastuzumab-based therapy, no HER2-targeted agent is available for patients with HER2-positive esophagogastric... 
IRINOTECAN PLUS CISPLATIN | SUPPORTIVE CARE | GASTROESOPHAGEAL JUNCTION | ONCOLOGY | RANDOMIZED PHASE-III | ADENOCARCINOMA | ADVANCED GASTRIC-CANCER | COMPARING IRINOTECAN | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | PACLITAXEL
Journal Article
Cancer and metastasis reviews, ISSN 0167-7659, 09/2016, Volume 35, Issue 3, pp. 439 - 456
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2002, Volume 20, Issue 8, pp. 1996 - 2004
Purpose : We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous-infusion... 
5-FLUOROURACIL | ONCOLOGY | ADVANCED GASTRIC-CANCER | HIGH-DOSE METHOTREXATE | DOXORUBICIN | PHASE-II | ADRIAMYCIN | COOPERATIVE GROUP | QUALITY-OF-LIFE | EUROPEAN-ORGANIZATION | COMBINATION
Journal Article